xCures Announces Advisory Appointments

xCures announced today that it has named David Hartford and Elizabeth Hutt Pollard as senior advisors.

“We are extremely pleased to be able to draw on David and Elizabeth’s knowledge and experience as xCures is changing how advanced cancer patients are served in their treatment,” said Mika Newton, CEO of xCures. “David’s expertise in investing at the intersection of technology and life sciences will bring us a valuable perspective on how we interact with the biopharmaceutical companies and the investor community. Similarly, Elizabeth’s work in the business of advancing paths to treatment and medical research provides us yet more understanding to further our work in Perpetual Trials and Virtual Tumor Boards.”

About David Hartford

David Hartford was a founding partner of Calibrium AG (formerly known as Aeris Capital) and now is senior advisor to the firm. Calibrium manages funds for the family office of a successful European entrepreneur, as well as for his foundation, one of the largest in Germany. In addition to his role at Calibrium, David serves on a number of boards of directors in support of early-stage technology companies.

David has more 40 years of experience in the U.S. and Europe as a private equity investor, venture capitalist and entrepreneur. During his career, he has also undertaken direct C-suite roles and been a practicing securities attorney. David began his career as a systems specialist with Rockwell International.

David received his BS from the University of Pittsburgh, his JD from the University of Pennsylvania, and completed the Advanced Executive Program “Competing in a Global Environment” at The Anderson School at UCLA.

About Elizabeth Hutt Pollard

Elizabeth Hutt Pollard, is Executive Chair of Applied Silver, Inc. a privately held company addressing soft surface infection prevention in the health, athletic and consumer markets. She currently serves as a strategic advisor to several early-stage life science companies and holds leadership positions in YPO, the premier leadership organization of chief executives in the world.

Prior to joining Applied Silver, Elizabeth was CEO of NuGEN Technologies, a global leader in genomic sample preparation products enabling scientists and clinicians to discover genetic signatures and predict disease risk and drug response, potentially shortening the path to treatment. Elizabeth has also held US and International management roles with Tripos, Affymetrix, and Life Technologies, during significant growth phases of these life science businesses

Elizabeth spent three years as a research associate at the University of Michigan in the Departments of Hematology/Oncology, where she made the decision to have a broader impact on medical research by transitioning into a career within the commercial biotechnology sector. She holds a BA in Chemistry from Michigan State University and an M.S. in Administration from Central Michigan University.